Date: 2014-11-25
Type of information: Series B financing round
Company: Cell Medica (UK)
Investors: Imperial Innovations (UK) Invesco Perpetual (UK) Woodford Investment Management (UK)
Amount: £50 Million (€ 31.5 million)
Funding type: series B financing round
Planned used: Cell Medica will use the investment capital to progress further the development of cellular immunotherapy products with the potential to transform the treatment of cancer and infectious diseases. The Company’s lead oncology product, CMD-003, is under investigation in the CITADEL Phase 2 clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus. Comprised of the patient’s own immune cells, CMD-003 offers the potential for a targeted approach to cancer treatment with very limited side effects or toxicities. In the infectious disease field, Cell Medica is developing Cytovir CMV for the treatment of cytomegalovirus infections and Cytovir ADV for the treatment of adenovirus infections. Both applications are aimed at treating and preventing infections in patients who are profoundly immunosuppressed following a bone marrow transplant. The clinical development of Cytovir CMV has been funded in part by The Wellcome Trust.
Others: * On November 25, 2014, Cell Medica, a leading cellular immunotherapy company, announced the closing of a £50 million (€ 31.5 million) Series B investment round with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management.
Therapeutic area: Cancer - Oncology - Infectious diseases
